4142:TPE
Adimmune Corp
16,35 NT$
arrow_downward
−1,51%(−0,25) 1 p
6. nov, 13:30:04 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
16,05 NT$
Kõrge
16,50 NT$
Madal
15,65 NT$
Turu kapit.
7,02 mld
Keskm. maht
1,08 mln
Maht
2,16 mln
52 näd kõrgeim
22,50 NT$
52 näd madalaim
15,65 NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29 mln
Töötajate arv
564
Ava
16,05 NT$
Kõrge
16,50 NT$
Madal
15,65 NT$
Turu kapit.
7,02 mld
Keskm. maht
1,08 mln
Maht
2,16 mln
52 näd kõrgeim
22,50 NT$
52 näd madalaim
15,65 NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29 mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
QuotedData
·
36 minuti eest
Tech trusts tumble in global AI sell off as Nasdaq crashes 5.5% and Japan's Nikkei slides 6% into a "bear" market
www.tmgm.com
·
1 tunni eest
Dow Jones futures fall following steep Wall Street sell-off, NFP data awaited
Yahoo Finance
·
7 tunni eest
S&P 500, Nasdaq, Dow Futures Dip As Investors Step Back From AI And Tech With Nasdaq In Correction Territory — NVDA, AAPL, UBER, SOXX In Focus
The Motley Fool
·
5 tunni eest
The Nasdaq Plunges 5%. What the Data Center Crash Means for Investors
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta